Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. [electronic resource]
Producer: 20050926Description: 1333-9 p. digitalISSN:- 0041-1345
- Adult
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Daclizumab
- Drug Therapy, Combination
- Female
- Graft Rejection -- epidemiology
- Heart Transplantation -- immunology
- Humans
- Immunoglobulin G -- therapeutic use
- Immunosuppressive Agents -- therapeutic use
- Incidence
- Infections -- epidemiology
- Male
- Middle Aged
- Multivariate Analysis
- Postoperative Complications -- classification
- Registries
- Survival Analysis
- Time Factors
- United States
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.